These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38035319)

  • 1. Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.
    Langley PC
    Innov Pharm; 2023; 14(1):. PubMed ID: 38035319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER).
    Langley PC
    Innov Pharm; 2020; 11(3):. PubMed ID: 34007634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICER, ISPOR AND QALYs: Tales of Imaginary Worlds.
    Langley PC
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies.
    Langley PC
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More Unnecessary Imaginary Worlds - Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease.
    Langley PC
    Innov Pharm; 2020; 11(2):. PubMed ID: 34007618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM).
    Langley PC
    Innov Pharm; 2022; 13(2):. PubMed ID: 36654699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.
    Langley PC
    Innov Pharm; 2021; 12(1):. PubMed ID: 34007677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma.
    Langley PC
    Innov Pharm; 2022; 13(2):. PubMed ID: 36654713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Facilitating bias in cost-effectiveness analysis: CHEERS 2022 and the creation of assumption-driven imaginary value claims in health technology assessment.
    Langley P
    F1000Res; 2022; 11():993. PubMed ID: 36226039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis.
    Langley PC
    Innov Pharm; 2021; 12(4):. PubMed ID: 36033123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value Assessment in Cystic Fibrosis: ICER's Rejection of the Axioms of Fundamental Measurement.
    Langley PC
    Innov Pharm; 2020; 11(2):. PubMed ID: 34007612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review.
    Langley PC
    Innov Pharm; 2021; 12(3):. PubMed ID: 35601587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure.
    Langley PC; McKenna SP
    Innov Pharm; 2021; 12(2):. PubMed ID: 34345508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy.
    Langley PC
    Innov Pharm; 2019; 10(3):. PubMed ID: 34007562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement, modeling and QALYs.
    Langley PC; McKenna SP
    F1000Res; 2020; 9():1048. PubMed ID: 33093950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.
    Langley PC
    Innov Pharm; 2020; 11(4):. PubMed ID: 34007652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index.
    Franklin M; Hunter RM; Enrique A; Palacios J; Richards D
    Value Health; 2022 Jun; 25(6):1018-1029. PubMed ID: 35667775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports.
    Ronquest NA; Paret K; Gould IG; Barnett CL; Mladsi DM
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1601-1612. PubMed ID: 34714108
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.